Literature DB >> 12857572

Lymphoma development in a patient receiving anti-TNF therapy.

Panayiotis D Ziakas1, Stavroula Giannouli, Athanasios G Tzioufas, Michalis Voulgarelis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12857572

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

Review 1.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

2.  Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors:  Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

Review 3.  [Systemic psoriasis therapy - the next step. Adalimumab].

Authors:  G Wozel; M Sticherling
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

Review 4.  TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.

Authors:  Ruwaida Ben Musa; Lydia Usha; John Hibbeln; Ece A Mutlu
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 5.  Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis.

Authors:  J Franklin; M Lunt; D Bunn; D Symmons; A Silman
Journal:  Ann Rheum Dis       Date:  2005-10-25       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.